Kronox Lab Sciences: Board Reconstituted, Key Appointments and Resignations Announced
Kronox Lab Sciences has seen a significant change in ownership with the transfer of 64.26% stake. The board has appointed Suresh Kalra as MD & CEO, and Sunil Malhotra, Harsh Malhotra, Amit Kumar Sharma, Anuradha Suneet Maheshwari, and Dhananjay Tapasvi as directors. Shashikant Bharuka is the new CFO. Several senior management and directors have resigned.
The transfer of a majority stake (64.26%) signifies a change in control of the company. The extensive changes in the board of directors and key management personnel, including the appointment of a new MD & CEO and CFO, will have a substantial impact on the company's future strategy and operations.
The announcement involves a change in control and significant changes in board and management. While a change in ownership can be positive or negative depending on the acquirer's strategy, the numerous resignations and appointments indicate a period of transition rather than a clear positive or negative outcome at this stage.
Kronox Lab Sciences Limited has announced significant changes to its board and management. The company has completed the transfer of 2,38,44,000 equity shares, representing 64.26% of its total paid-up equity share capital, from Mr. Ketan Vinodchandra Ramani, Mr. Pritesh Vinodchandra Ramani, and Mr. Jogindersingh Gianchand Jaswal (Sellers) to Indo Borax & Chemicals Limited (Purchaser).
Following this transaction, the Sellers collectively hold 9.95% of the voting share capital, and they, along with other members of the promoter group, have ceased to be part of the promoter/promoter group. The board of directors has taken on record this transfer.
In a significant board reorganization, Suresh Kalra has been appointed as an additional Director (Managing Director and Chief Executive Officer) for a period of 5 years. Sunil Malhotra and Harsh Malhotra have been appointed as additional Directors (executive and non-independent) for 5 years. Amit Kumar Sharma, Anuradha Suneet Maheshwari, and Dhananjay Tapasvi have been appointed as additional Directors (non-executive and independent) for 5 years.
Furthermore, Shashikant Bharuka has been appointed as the Chief Financial Officer and Key Managerial Personnel for a term of 5 years.
Concurrently, several key personnel have resigned. Jogindersingh Gianchand Jaswal has resigned as Managing Director, effective immediately. Ketan Ramani and Pritesh Vinodchandra Ramani have resigned as executive directors. Samir Gadhiya has resigned as Chief Financial Officer.
Additionally, independent directors Parth Shah, Krutika Arunkumar Negandhi, and Satish Kumar have tendered their resignations, effective September 29, 2026.
Following these changes, the company's board committees, including the Audit Committee, Nomination and Remuneration Committee, Stakeholders Relationship Committee, and Corporate Social Responsibility Committee, have been reconstituted with new members.
Finally, the company has approved the execution of consultancy agreements with Mr. Jogindersingh Gianchand Jaswal, Mr. Ketan Ramani, and Mr. Pritesh Vinodchandra Ramani.
What to do with a filing like this
Kronox Lab Sciences Limited filed this with the NSE as a statutory disclosure, categorised under key management changes. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Kronox Lab Sciences Limited. Read the original for the full detail.